




PHARMACEUTICAL 2021

Harmony Biosciences Holdings Inc.
Rank 264 of 402





RealRate

PHARMACEUTICAL 2021

Harmony Biosciences Holdings Inc. Rank 264 of 402



The relative strengths and weaknesses of Harmony Biosciences Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Harmony Biosciences Holdings Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 62% points. The greatest weakness of Harmony Biosciences Holdings Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 95% points.

The company's Economic Capital Ratio, given in the ranking table, is 34%, being 13% points below the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	262,891
Cost of Goods Sold	27,738
Intangible Assets	162,343
Liabilities, Current	134,539
Liabilities, Non-Current	195,355
Other Assets	902
Other Compr. Net Income	0
Other Expenses	55,824
Other Liabilities	0
Other Net Income	-53,930
Other Revenues	159,742
Property and Equipment	938
Research and Development	19,448
Selling, General and Administrative Expense	39,746

Output Variable	Value in 1000 USD
Assets	427,074
Liabilities	329,894
Expenses	142,756
Revenues	159,742
Stockholders Equity	97,180
Net Income	-36,944
Comprehensive Net Income	-36,944
Economic Capital Ratio	34%